The company expects that Blueprint's informatics capabilities in particular will improve variant interpretation and reporting across all its genetic test offerings.
Abcam said that acquisition will help it build out a discovery engine for developing novel edited cell lines and support its knockout validation initiative.
Illumina officials discussed several issues with investors, including the new Qiagen partnership, while at ASHG the firm introduced reagent kit upgrades.
The combined company will use RNA-based tools to enhance drug development by identifying the right patients for oncology drugs and potentially improving drug response rates.
